Musculoskeletal Pain – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

 Musculoskeletal Pain conditions are typically characterized by pain (often chronic pain) and limitations in mobility, agility, and functional ability, reducing people's ability to work and participate in social roles, with associated effects on mental wellbeing and, on a broader level, effects on community prosperity. Osteoarthritis, back and neck pain, fractures associated with bone fragility, injuries, and systemic inflammatory conditions such as rheumatoid arthritis are the most common and disabling musculoskeletal disorders. There is a need for a more comprehensive approach to work retention and rehabilitation that considers the complex and multifaceted nature of presenteeism, absenteeism, and long-term incapacity for work. Chronic pain conditions affecting the musculoskeletal system often have no cure, and people with these conditions are among the most affected by disability in our community. Musculoskeletal pain is associated with musculoskeletal (MSK) conditions that affect the muscles, bones, and joints. They are often, but not always, associated with injury or old age. Painful MSK conditions include arthritis, back pain, neck pain, shoulder pain, foot pain, and osteoporosis. The most effective way to manage pain from MSK conditions is with multidisciplinary pain management and self-management. The condition may be improved with joint replacement surgery or a spinal cord stimulator implantation by a specially trained pain specialist in a few cases.

 

The prevalence of Musculoskeletal pain ranges from 10 MN to 12 MN among 18 years and older population in the USA.

 

The competitive landscape of Musculoskeletal Pain includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Musculoskeletal Pain across the 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Musculoskeletal Pain Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Musculoskeletal Pain – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Cannabidiol       Pure Green       Phase 2

2          EB-001 Bonti, Inc.         Phase 2

3          Ibuprofen gel     Brainfarma Industria Química e Farmacêutica S/A            Phase 3

4          Cunermuspir     Mitosynergy LLC           Phase 2

5          S-Ibuprofen       Aponia Laboratories, Inc.           Phase 2

6          Etodolac-lidocaine         MEDRx USA, Inc.         Phase 3

7          SST-0225         Strategic Science & Technologies, LLC  Phase 3

8          Diclofenac sodium         Novartis            Phase 3

9          Tapentadol        Grünenthal GmbH         Phase 2

10        ACP-044           ACADIA Pharmaceuticals Inc.    Phase 2

Continued